Biocompatibility in heparin-coated extracorporeal circuits

Perfusion

Volumn 11, Issue 3, 1996, Pages 256-263

  Hsu, Li Chien ^a  

^a BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMATERIAL; HEPARIN; PLASMA PROTEIN;

ADSORPTION; BIOCOMPATIBILITY; BLOOD CLOTTING; CARDIOPULMONARY BYPASS; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; INFLAMMATION; LEUKOCYTE; PRIORITY JOURNAL; SURFACE PROPERTY; THROMBOCYTE ACTIVATION;

EID: 0029835945     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1177/026765919601100311     Document Type: Conference Paper

References (32)

1. Chenoweth DE, Cooper SW, Hugli TE et al. Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med 1981; 304: 497-503.
2. Butler J, Rocker GM, Westaby S. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993; 55: 552-59.
3. Dreyer WJ, Michael LH, West MS et al. Neutrophil accumulation in ischemic canine myocardium. Insight into time course, distribution, and mechanism of localization during early reperfusion. Circulation 1991; 84: 400-411.
4. Colman RW, Scott CF, Pixley RA et al. Effect of heparin on the inhibition of contact enzymes. Ann NY Acad Sci 1989; 556: 95-103.
5. Hsu LC. Principles of heparin coating techniques. Perfusion 1991; 6: 209-19.
6. Gravlee GP. Heparin-coated cardiopulmonary bypass circuits. J Cardiothorac Vasc Anesthesia 1994; 8: 213-22.
7. von Segesser LK, Schilling J, Leskosek B et al. Surface treatments for perfusion devices. Perfusion 1994; 9: 197-205.
8. Hsu LC. Duraflo II heparin immobilized cardiopulmonary bypass circuits. In: Ott RA, Gutfinger DE, Gazzaniga AB eds. Cardiac surgery: state of the art reviews. Philadelphia, Hanley & Belfus, Inc. 1993; 7: 265-73.
9. Baier RE, Dutton RC. Initial events in interaction of blood with a foreign surface. J Biomed Mater Res 1969; 3: 191-206.
10. Cornelius RM, Brash JL. Identification of proteins adsorbed to hemodialyzer membranes from heparinized plasma. J Biomater Sci Polymer Edn 1993; 4: 291-304.
11. Young BR, Lambrecht LK, Albrecht RM et al. Platelet-protein interactions at blood-polymer interfaces in the canine test model. Trans ASAIO 1983; 29: 442-46.
12. Wendel HP, Heller W, Hoffmeister HE. Pathway of platelet protection in heparin-coated devices and its significance for cardiovascular surgery. Trans Soc Biomater 1995; 21: 281.
13. Edmunds LH Jr. Blood platelets and bypass. J Thorac Cardiovasc Surg 1989; 97: 470-71.
14. Tong SD, Rolfs MR, Hsu LC. Evaluation of Duraflo II heparin immobilized cardiopulmonary bypass circuits. ASAIO J 1990; 36: 654-56.
15. Gu YJ, van Oeveren W, van der Kamp KWHJ et al. Heparin coating of extracorporeal circuits reduces thrombin formation in patients undergoing cardiopulmonary bypass. Perfusion 1991; 6: 221-25.
16. Nakajima T, Ogawa M, Sasaki T et al. Clinical study of coagulofibrinolytic system and platelet function with Duraflo II coated cardiopulmonary bypass equipment. ASAIO Abstract 1994; 23: 61.
17. von Segesser LK, Weiss BM, Pasic M et al. Risk and benefit of low systemic heparinization during open heart operation. Ann Thorac Snrg 1994; 58: 391-98.
18. Ovrum E, Holen EA, Tangen G et al. Completely heparinized cardiopulmonary bypass and reduced systemic heparin: clinical and hemostatic effects. Ann Thorac Surg 1995; 60: 365-71.
19. th Annual San Diego Cardiothoracic Symposium Pathophysiology and Techniques of Cardiopulmonary Bypass, San Diego 1994; 14: 236.
20. van der Kamp KWHJ, van Oeveren W. Contact, coagulation, and platelet interaction with heparin treated equipment during heart surgery. Int J Artif Organs 1993; 16: 836-42.
21. Heller W, Wendel HP, Rifai R et al. Comparative studies on the haemo- and biocompatibility of a heparin-coated system in aortocoronary bypass surgery. Trans Soc Biomater 1995; 21: 282.
22. Pradhan MJ, Fleming JS, Nkere UU et al. Clinical experience with heparin coated cardiopulmonary bypass circuits. Perfusion 1991; 6: 235-42.
23. Toomasian JM, Hsu LC, Hirschl RB et al. Evaluation of Duraflo II heparin coating in prolonged extracorporeal membrane oxygenation. ASAIO Journal 1988; 34: 410-14.
24. von Segesser LK, Weiss BM, von Felton E et al. Perfusion without systemic heparinization for rewarming in accidental deep hypothermia. Ann Thorac Surg 1991; 52: 560-61.
25. Tong SD, Hsu LC. Non-thrombogenic hemofiltration system for acute renal failure treatment. ASAIO Journal 1992; 38: M702-M706.
26. Ovrum E, Brosstad F, Holen EA et al. Effects on coagulation and fibrinolysis with reduced versus full systemic heparinization and heparin-coated cardiopulmonary bypass. Circulation 1995; 92: 2579-84.
27. Tonnesen MG, Smedly LA, Henson PM. Neutrophil-endothelial cell interactions. J Clin Invest 1984; 74: 1581-92.
28. Gu YJ, van Oeveren W, Akkerman C et al. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993; 55: 917-22.
29. Jansen PGM, te Velthuis H, Huybregts RAJM et al. Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin coated circuits. J Thorac Cardiovasc Surg 1995; 110: 829-34.
30. Moen O, Hogasen K, Andersson C et al. Changed expression of adhesion molecules on granulocytes, monocytes and thrombocytes in heparin-coated cardiopulmonary bypass. Abstract Scand Assoc Thorac Surg 1995; 26.
31. Penka M, Hagman L, Halden E et al. Complement activation during cardiopulmonary bypass: effects of immobilized heparin. Ann Thorac Surg 1994; 58: 421-24.
32. Ovrum E, Mollnes TE, Fosse E et al. High and low systemic heparin doses with completely heparin-coated cardiopulmonary bypass: Activation of complement and granulocytes. Abstract Scand Assoc Thorac Surg 1995; 27.